Tag
This review analyzes the PORTAL study’s nomogram for predicting ADT-free survival in oligorecurrent prostate cancer, synthesizing evidence on PSMA PET-guided SBRT and the clinical utility of risk-based patient selection.
A Phase 1b study demonstrates that combining SBRT with the bispecific antibody cadonilimab (PD-1/CTLA-4) is safe and effective for refractory solid tumors, yielding a 23.8% response rate and 7.2-month median PFS in patients who failed multi
In the randomized phase II LUNAR trial, adding two cycles of neoadjuvant 177Lu-PNT2002 to stereotactic body radiotherapy (SBRT) for oligorecurrent hormone-sensitive prostate cancer significantly prolonged progression-free survival (17.6 vs
The PACE-C phase 3 trial shows that stereotactic body radiotherapy (SBRT) and moderately hypofractionated radiotherapy (MHRT) have comparable early toxicity profiles in intermediate- and high-risk prostate cancer patients.
